CA2169354A1 - Functional oxygenated composition containing phospholipids and fluorocarbon - Google Patents

Abstract

A composition contains certain nutrients, active and protective substances, as well as an oxygen carrier. Also disclosed is a process for preparing this composition and its use. The invention solves the problem of preparing skin care compositions with a high oxygen content which also contain further nutrients, active and/or protective substances at a reduced cost. The new functional oxygenated composition consists of (a) phospholipids and oxygen-loaded fluorocarbon or fluorocarbon mixtures. The proportion of fluorocarbon lies in the 0.2 to 100% by weight/volume range. The lipid fraction contains 30 to 99% by weight phosphatidylcholine in the form of asymmetric lamellar aggregates. The disclosed composition also consists of (b) a product obtained by gentle disintegration of suspensions or dispersions of cells of plant substances, bacteria or yeast by ultrasonic and/or high-pressure homogenisation under up to 25 MPa, and (c) a cosmetic or dermatological carrier suitable for use on the skin. This composition is based for its oxygen content on the synergy between fluorocarbons and the disintegration products.

Description

.~ - . -21 ~54 .~

Functional oxygenated composition cont~i n i ng phospholipids and fluorocarbon Description The invention relates to a preparation which contains nutritient, active and protective substances as well as an oxygen carrier. It furthermore relates to a process for the manufacture of such p~ tion and its use.

It is known to prepare certain active substances from plants or even from yeasts and to employ these in cosmetics or dellllatology. Included therein are inter alia proteins such as pero~cide dismutase (DE-OS 2417508; EP-A-19474). It has also already been proposed to encap~ulate active substances of vegetable origin in li~oso"le structures and to apply these to the skin.

Furthermore, cosmetic and dermatological products have recently been proposed which, with the aid of phospholipids having high phospllaliJ~lcholine contellls and fluorocarbons form novel asymmetrical l~mell~r structures and due to their good penetlation plopellies are capable of introducing high oxygen conlellls into the upper skin layers. Fluorocarbons are synthetic products, the manufacture of which, involves considerable costs and which for improved efficacy may be present in cosmetic plep~tions in amounts of 10 to 40~i.

The invention has as an object skin plcp~Lions which not only have a high oxygen content but also a content of further nutrient, active and/or p-oteeli~/e agents with simultaneous cost reductions.

According to the invention, the new functional oxygenaceous preparation comprises a) phospholipids and an oxygen laden fluorocarbon or fluorocarbon mixture, the proportion of fluorocarbon being in the range of 0,2 to 100% weight/volume, and comprising a phosphatidylcholine content of the lipid fraction of 30 to 99~ by weight in the form of asymmet~ical lamellar agglegates, 2.1 69:~54 b) a digestive 1~ l pl`~nlucl ob~ d by the mild digestive ~ l?ll~ by means of ultrasonics and/or high pressure homogenisation up to 25 MPa of suspensions or ,;olls of celts of vege~ble matter, b~ or yeasts, and c) a co~ ;c or de~ lologicat ca~ier S 'l~St~ s.~il~le for ap~lic~liol- to the skin.

If was found surprisingly that combined with a simull~leous presence of a~yl""-ellical l~mPll~r aggl~ates of lluul~bons and phos~l-olipi(l~ having a high pho3~hatidylGholine content on the one hand and, on the other hand, of dige~live ll~t..-~ t pluducls of celts of vegehble matter or yeasts camed by these aggiegal~s, an amount of o~ygen is present in the aggleg~t~s which is higher than can be ~ d from the fluoroc~l,oll content and the critical solubility le~ e.ature which can be set up therewith. This synergistic effect p~lmi~ a ~Ju~;l;o~- of the llulolu~t~on content with a s~ n~us ullluducLon of usefut ru~ ;o~js, active and ~r~ iv-t; ;,.ib~ g derived from the ~ t~ pl~ of the ~,t;ge~ble and yeast celts.

Advantageously green atgae, seeds, grains, barks, plant extracts are employed in the p'~ation~ serving as vegetable sul,sl~lces, during the mild digestive t~ ent of the cells of which, s~lbst~ are formed such as pl~t~ s, e~ c~, nucleic acids, vi~
hollllolles, fluoranoids, flavonoids etc. A particularly alvanlageous vegetable s~lbst~nce for the prepa.~lion accordillg to the invention is the bark of the M~ic~n Skin tree, the d~ivalive products of which have not yet been fully identifiçd, howeY~r, and which in combination with fluorocall ons or fluorocarl,on mi~ctures generate slirprisingly high o~cygen conlellt~ and anti~ a~oly effects in a plepa,dlion.

Also particularly valuable are those combinations in which high propollions of acids, selecled from acids such as fruit acids, e.g. malic acid, citric acid, tartaric acid, fumaric acid, succinic acid, gluconic acid as well as lactic acid are ploces~ with ~luo,u~t)ons to form p~c~ ûns which can be applied to the skin.

Likewise valuable are combinations with vitamins such as one or more of the group ~in A, ~ ~in B, vitamin C, vitarnin D, vitamin E, vitamin P as well as flavonoids, i.e. the ~h~lllacologically active glycosides of the flavones. These include in particular 2 1 ~354 also the bioflavonoids which are also known as vitamin-P factors, e.g. rutine, but also other flavonoids such as, for eAample flavonol, chrysin, g~l~ngin, apigenin, fisetinj luteolin, ~e~ )re.ul, ~Iu~,cclin, morin and their d~ ali~s in the form of biologically active ~ s.

Accordhlg to the invention, particularly active plcpal~lions include also those which in addition to the elevated o~ygen content contain active substances in the form of ~,i~;...-in.
comprising the vilamhl c~llll.hlations P-B-A or A-E-C or B-E-A.

Yeasts which are particularly suitable for the l~ l.ent are bakers' yeast, br~sls' yeast, wine yeast as well as yeast c~ h~ with pero~ide d;~ lA~e.

Bacteria, which are particularly suitable for the treatment are those of the class Py~~ cet~s such as PLyloplltllola C~C~(J1UI1I~ Ascollly~t~s such æ ~per~ s niger Kl, Ch~tollli~lll globosum, Penicillinum cL~soge.l~.n; Basidolll~ccl~s such as Coniophora celebella, Corticium confluens; Deuteromycetes such as Glocospolium fructigenum,FIJ~- ;Un~ UA~ U1U1n~ ....Z. ;A solani etc. This list is by way of eAarnple.
i For the ~ Jc~;on of the asy...~-çl ;c l~mPll~r agglc~at~s a large .~.nbe~ of nuoluc~l,~ns can be clllplo~d, e.g. aliphatic straight chain and blanclled chain fluoro~ll~nPs, mono- or bicyclic and optionally fluoroalkyl s.,l~ ~ fluorocycln~lk~nps~ pclll~lo~ çd aliphatic - or bicyclic ~minçs~ bis- (perfluoroalkyl) e~ nes~ perfluoropolyethers or their mi%tures.
Those fluorocarbons such as perfluorodecalin, F-butyltetrahydrofuran, perfluorotributylamine, perfluoroctylbromide, bis-fluoro(butyl)ethene or bis-fluoro(he~yl)ethene or C6-C9 pe~ o~o~ll~ne~s are par~cularly p1ef~l1c d.
In this conteAt the proportion of fluorocarbons is in the range of 20 to 100% w/v, preferably in the range of 40 to 100%. A particularly l~le~ll~ d range is that of 70 to 100% w/v.

The term "fluorocarbons" as used herein denotes perfluorinated or highly fluorinated carbon co~ ounds or mLl~tures which are capable of t1~spolling gàses such as 2 and CO2. Highly n.,~ ed hy~uc~l~o1l c~ )ou1lds within the illcP~1ing of the inven~on are .

those in which most hyd,~Jgen atoms have been substituted by fluorine atoms so that a higher degree of s.~ litulion does not necf ss~l ily increase the gas transporting ability.
This is usually ~ in~ in those cases where about up to 90% of the llydlogen atoms have been substituted by fluorine atoms. Within the conte~t of the present invention~fluorocarbons are preferred in which at least 95% of the hydrogen atoms have bee~
s.ll,s~;luled, plerel~bly 98% and most p,efe,dbly 100%.

Natural phospholipids such as soy~leci~hin and egglecithin, synthetic phospholipides as well as hydrogenated lecithines, e.g. phosphorlipone H or partly hydrogenated phospholipids are employed as phospholipids. In these phospholipids the content of pho"~h~l;.lyl~ holine is in the region of 30 to 99~ and in particular of 70 to 90%.

Besides phosphatidylcholine, there may also be pl~ent lysoleci~l-ine in the concen~lation range of 0,1 to 10% by weight and/or charged phospholipids such as phosphatidylethanolamine, n-acetylphosphatidylethanolamine or phosphatide acid in a con~ ~aLion range of 0,1 to 30% by weight.

These phophorlipid-stabilised aggregates, in contrast to the known aqueous liposomes (vesicles) carry in their nucleus hydrophobic fluorocarbons which have the ability to ll~U1S~1l oxygen. Their iQt~r~cial C~ stabili~tion takes place pJim~rily by way of a mono-layer with inverse ~tlu~ e and this may be followed by a build up of bi-layer strata.
of the ~ ;~ of the their shu~ al all~ngem~nl, these novel ag~gat~s are ~efelled to as asymmetric lamellar oxygen carriers. Their unusual colloid chemical shbiliq is ~ ly deli~ed from the l~mPll~r sllut;~ and the ~ulr~ce chafges of the aggl~gat~ s. The latter is caused by the se~ on of suitable pllos~hol;rids or their nl~lules of natural as well as synthetic character. Por an advantageous effect in this sense, pho~l olipids, in particular pl~o~!~ ylcl~ol~ in the afol~id col~r~ dlion ~ange of 30 to 99% in conjunclion with Iysolf~ at à collc~nllation of ~,1 to 10% and/or ch~ged phospholipids in the concenllation range 0,1 to 3~ weight % are primarily responsible.
The effect of the phos~holipids under ~ ;u~ion is ~ ledd by ~ll~ ~O~ g negative æta potentials and by the measurement of charge densities (by titration with a cationic polyelectrolyte). An important criterion for the employment of the fluorocarbon ~ 21.69354 -agglG~,at~s is their skin ~n~ on as a r~n~;l;oll of the critical solubility le~ e of the se,lecled nl~vlu~bvlls or lluvlucall,on ~ ~. (c.f. DE-A-42 21 255).

It is also possible to employ an a lueous ~uoloca,t,on emulsion having a content of 1 to 8 mass % of a non-ionogenic tenside as emulsifier, a particularly a~lv~ullageous content o~
fluoroc~bons being in the range of 40 to 100% (w/v), in particular 70 to 10a~. Per-nuv~ d imino-bis ~olyu-~alkylenes), polyvAyGlhylelle-polyu,y~opylene upvlylnels~etho~cylated sorbitol fatty acid esters, non-ionogenic etho~ylated fluorotensides and/or elhv~lal~d poly~ ylcllGglycvls may be employed as non-ionoge,~ic tens~de.

A particularly advantageous digestive treatment product is obtained by an ultrasonic digestive lre~ using an ulllasol~ic con~ u~s flow cell in which the sy.lotlude projects as to l~C2 to 2/3 its length into the continuous flow cell, the angle of the synotl-,de in the sound G~-~JGSIilG vessel being in the range of 80,5 to 88,5, the ratio of ilnm~siOll length of the synotrode (in mm) to the sound irradiated volume (in ml) being set to a value in the range of 1:1,1 to 1:20 and the ratio of immersion length of the synotrode (in mm) eO the solids content of the medium to be irra~ ted ~ith ultrasonic (in mass %) being in the range of 0:0,02 to 1:2,2.

The surprising effect of the combination of asymmetrical lamellar aggregates and the digestive l~e~ nt products of vegetable and yeast cells is particularly ill~plessive in the case of treating pero~ide dismutase enriched yeasts which provide a~high content of pero~ide ~ (SOD). Since SOD acts in the skin as a radical capl.l,ing agent and catalyses the ~ Lion 2 2- + 2 H+ ~ H202 ~ 2 it is per se a particularly advantageous component in cosmetic or de~matalogicale~al~tions. Ho~ r, other radical ca~ ing agents may be used as ~vell, which are suitable for binding free o~cygen radicals, for ~ pl~ vitamin E, P.

A further advantageous preparation comprises the feature that the vegetable treatment product is produced of cells of the Me~ican skin tree~ wherèby a particularly anti~ c,. ~ oxygen-rich pl~nlu~ t is c~laillcd.

1 2]6~54 The invention also relates to a process for the n~A~ r~ of the functional okygenace~us plep~ ;on. The yl~ess is ~h~ ;.ced in that (a) suspensions or dispersions of cells of vegetable matter, bacteria or yeasts are dig~li~cly treated by mild ultl~sol~ic lle~ and/or high ~ ulc ho...ogeni~tion up to 25 MPa, (b) phospholipides are emulsified with an oAygen-laden nuor~l,on or fluoloc~lo Il~iAlulc in an a~ eous l-~eAi~ , the ni~O~ content being in the range of 0,2 to 10~)96 wei~;hUvolull.e and the content of pho~l~zt;dyl~holine ~ o~ ;ne to 30 to 99 mass %.
(c) the digestive llr~ product of (a) being miAed with the ernnlQ~ion (b), and (d) the asymmetrical lamellar aggregates obtained by (c) which incorporate the digestive l~ rl~ products (a) are inco~ ted in a carrier suil~l~ for application to the skin. In this contP~t, the lluoloc~lJol~ l~e may also be a n~o~-)c~t,on emulsion with non-ionog~nic tenQ;des as e;Aplained fur~her above.

It is particularly advanhgeous to carry out the cell digestive tre~tme.nt ultrasonically according to the pn:)CeSS described in DE patent application 42 41 154.8. This process, due to the special arrangement of the synotrode in an ultrasonic continuous flow cell, results in an econo-- ical and mild digestive lle~l~"- ll~ of the cells and provides for optimal yields of useful digestion products such as proteins, vitamins, enzymesj etc. In this conteAt, solids concç~lt~tions may be present in the me~ m to be subjected to ultrasonic in the range of 0,5 to 65 mass %. A particularly a.l~ ag~ol s s~nolLude angle alno~ls to 85,5. The a-llpLlude is plefeldbly in the range of 20 to 70.

A further possibility for the digestive treatment of the cells resides in high pressure holllog.~--i.~tion which can be col-J-.ct~ with ~ lC applica~iolls of up to 25 MPa (about 250 al.l,ovph~ ,s). It is also pos~le in special cases to colnbille bo~ pluC~~ S.
! ~
The u~enLion also relates to the use of the funcHorql oAy~e~lA~ s p~ ;ons i~
- the active ~.~bs~;~nc~s as de3c- ;I.ed above for the ~imnl~ eQlis supply of the skin with high o~ygen cont~ and with one or more ~,~I,s~ s of the group ~ ielll~; active 5~bs~n~, p~vt~clive agents and ph~...~ceulicqlly active ~ll,st~nces. These s~bs~lces may have an effect on the skin, nd/or tne tissue lu~ e~ the skin.

;~
- 2 1 693~4 , A~lo~liate formulations may be formulated with a carrier as used for costmetic or de~latalogical purposes to form ointm~nt~ creams, lotions, aqueous solutions, alcoholic t~L~ S, pastes, ~wdel 7~ gells, tincl.n~7, etc., to form skin-care agents, sun pluteclion formulations with UV absollJGl 7~ ~ming agents, fat repleni~hing after-shaves, cle~n~ g lotions and oils, enc~psul~ted radical capturing agents, formulations against p.egna~ X
stretch marks, hair and scalp care agents, bath oils, fitness friction agents, etc.

For this pul~se further pl~ l active S.~St~i~Cf~P7 may optionally be inl.u~ ced into the fonnllt~ion. These inchlde, for e,.~ le pharmacological active substances in the form of dermatological systemic active substances, including cytoshtics, cancerostatics, immunomodulators and vaccines, in particular those of the following group: dermatological active s~l,st~lces such as, for e~cample, virostatics or virocidal medications, anti-mykotics, heparines (e.g. heparin calcium, heparin sodium, low molecular weight heparines), antibiotics, corticoides, anti-infectives, anti-acne agents, local ~n~esthetics, antiphlogistics, antihistamines or antipsoriatics; systemic active agents such as, for e~camplej non-steroidal analgesics/antirheumatics (e.g. diclofenacsodium, diclofenacdiethylamine saltj etofçn~mate, flufen~min acid, 2-hydro~yetllylsalicylate, ib~l,rorelle, indomethacine, piro~icam), opiatereceplûLagonists and -antagonists (e.g. buprenorphine, fentanyle, pentazocin, pethidin, tilidin, tramadol, nalo~on), histamine antagonists ~e.g.
l~ t~'e, chl~ hf-~l-"~ e-HCI, c~ s~ hy~ iru~ 1der~ ~t~7 pheniraminhydrogenmaleate), insulines, regulatory peptides and their inhibitors (e.g.
adalohy~)oph~3e holmon s and their ~nhil,iluls~ neulohy~p hu~lnoAes~ hypv~ mlJ$
hollllol~s), s~ali~es/llyl~n~)lics (e.g. ~1;Q~ F;n~);
active s~ nc~ of the group cylOst~ks~ cancerosh~cs, ;Inn~ eQdul~lols~ cines.

A plcre.led dermatalogical active ~u~s~nce is~ for e~ample, lù3e -Z~ acid or anotl.e~
virucide or virustatic active su~sl~lcc occuring in plants. A p,~f~ d s~lel~lic active substance is, for e~ample, a low molecul~r or high molecular weight heparin, an oligopep~dde or a poly~Lide.

- 2 1 ~3~4 .~ .

Further preferred active substances are vitamins (E, A, B, C), muramylpeptides, do~orubicin, gentamycin, gramycidin, de~tnethason, hydrocollisone, progesterone,pre~lnisolone as well as their ~ o~1 salts of acids or bases.

The abovementioned dermatological active substances may, if necessAty, have added~
thereto one or more anti-o~cidants.

The invention is to be further ~ lJl~in~l in what follows by way of e~amples.

E~ample 1 Production of Fl~ ~b~n E mulsion 50 ml of a 10% aqueous phospholipid solution (soyalecithinj 40% phosphatidylcholin (PC)) a holllogel~ised jointly with 80 g of a high pur~ty rluol~ul~n n~L~lule co~ e no H atoms (90% l,elllllo~ lin, 10% ~-dil~ly~ e~ G~ critical solubility tc~n~lule 26C) with an ulllasol~ic r~ e~dlor and application of ice cooling until the p~Lclc size of the particles has ~ ;n~ an average ~ t~r of 244 nm. From 31P-N~ m~GIIIGIIlS
the l~mell~r :~llU~ilUl~; of the agglGgates of fluGluc&ll~oll and phospholipids is a~ Gnl as well as by virtue of the typical signal width from el~llun-l.liclu~l s.

The agglGgale dis~Gl~ion can be mi~ed without problems and ~ 0ul errG~ g its stability with suitable alcohols (eth~nol, propylenegl~col, gl~cel~l) for pul~o3es of ster~ ng. An addition of 30 ml ethanol induces sterility, whereafter the resultant dispersion has the following culllpos;Lion:
62 % w/v flu~ s 9,7 % plo.~ lipids 19 % ethanol The æta ~l~ntial of minus 61 mV ~el~lollclldt~s a ne~al;~,e surface charge genel~lGd by the ~!-as~ olipids r~sl-lting in an elocllast~lic stabiliq~ti--n of tlle dispersian.

,?

Production of the D;~t.o~ Product of Yeasts 23,5 mass % backers' yeast 10,0 mass 96 gly~~
5,5 m~s ~0 p,~ nglycol q.s. ~li.cti11ed water.

The distilled water is first introduced at S to 7C into a conl;~ine~. The yeast is lis~l~d therein with agitation. Thereafter the glycelin and the propyleneglycol aré added to the su.~æn~.ion.

The ho.l,ogeneous yeast suspension is passed by means of a pump through an ulllasollic conlimlous flow ap~alatus and is s.~ led there to ~ ~nic l.~l~ n~ This results in a mild cell digestion and the lCCOV~;ly of the active cellular illgl~iiellt~ (e.g. ~r~t~ins such as Zn + Cu-perox~ iclll~ e; vilal,~ns such as vitarnin-B co rl~'C; Vital~ A, vitamin E).
The l)al~llt;~l~ in the cell were the follo~^ving:
lilude 55 ~nvt,ode angle 85,3 through flow velocity 1 l/h overall v~Jlullle of the COI~ luuS flow vessel SS0 ml length of s~nullude in vessel 30 mm solids content 23,5 mass %
digestion rate 95 - 99%
The ratio of ~ynolrode length: volume: solids colit~-nt amounted to 1: 18: 0,8. The overall length of the synotrode allloullt~d to S0 mm. The ratio of synotrode length in the vessel to the overall length tL~erul~ amoullled to 0,6.

The Production of the Cosmetic Preparation i The digested yeast suspension was centrifuged. 30% of t~e centrifugate enter into the nuoluc~l.oll aggl~;gates. The combination was added as an active substance comple~c to -. the O/W emulsion.

s-; ` 2 1 6q354 . ~ , O/W Emulsion Phase A:

glycel~lst~le 3,5%
stearic acid 2,0%
cetylalcohol 2,0%
p~lll;nocoQ 1,5%

Phase B:

.li~till~d water q.s.
C~tJO~ 0,7%
proplylell~lycol 3,0%
aL~e o,5 %

Phase C:

TEA active substance comple~ with dig~t~d yeast 10,0%

The Phases A and B were s~alately heated to 75C and mi~ed homogeneously. At less than 40C the active ;,~t~lce complex was added with a~i~

Example 2 ~n.~te~d of the yeast digestion product accolding to E~ample lf a digestion product of the bark of the Me~ican skin tree was plod~.ced having the following col-lpo~;lion 35 mass ~ skin tree, pulverised 5,0 mass % gl~c~,in S,0 mass % ~r~ylelleglycol q.s. ~ illed water.

~;
21 6~354 .

The pr~sillp took place at 15 % in a manner similar to that in ~ample 1. In doing so~
the synotrode angle was set to 87,0 j the amplitude to 65~ the synotrode length in the vessel to 33,2 mm and the volume of the throughflow vessel amounted to 650 ml at a throughflow velocity of 0,5 I/h. A digestion ràte of 9696 was attained for a solids conli~onenl input of 35 mass ~O. The ratio of synokode length: vol~lme: solids conlt;l1l amounted to 1: 19: 1. At the same synotrode length, as in Example 1, the ratio of ~lloll~)de length in the vessel to overall length was 0,664.

.
'' The as~ mPl1~r aggl~at~s, on the basis of ~,~ o,~Jdec~lin were mixed in the ~' following Illaunef with this digestion ~r~lucl to form a cos~ .!ic l)ie~.i~;on . ~
30~O of the centrifugate enter into the fluolocallon aggregates and were mixed into the O/W emulsion under the same con-lition~ as in T7 ~ P1E 1.
Furthermore, a yeast digestion product was mixed into the preparation to result in a mi~ture in the ratio of yeast in the fluorocarbon aggregate: Mexican skin tree in ~1UO1~l~On agg~gale equal to 2: 1.
From the following Table 1 the C2~ontent in the O/W em1-lsion after ~lition of the active sal,.hn(,~e co..lponlls is appa.e~

J

-.

216q354 Table 1 Product O~cygen content at 20Clppm c T..~-.-~li~l~l~ after after 24 h after 4 Plud~ ;on weeks O/W base (accol.lhlg to e,~al~'e) ~lvilllolll active sl~l.st~nces 15,5 15,9 15,0 OIW (accol~lhlg to ~ ple) with nu~ol~c~l oll agglegd~ 25 % 65,6 65,0 64,9 OIW (acconling to e~carnple) with 10% digested yeast ce~iru~at~ 17,9 18,2 18,5 r OI W (acco~llh~g to e~ ,le) with 10% of active s~jt~lce coll~bhld~oll; lluor~l~on aggl~dtc; + 10% digested . yeast cen~if~gate 62,5 65,0 66,2 ,; O/W (accor~ g to e,.all,pl~) with 10% of ac'dve s~-bt~loe colllbi~ ion; fluol~all~on ag~cgdte + 10% digested l~e.ic:~n skin ~ee celll,ifugatt 18,0 17,8 17,6 OIW (accordillg to e~l,ple) - with 10% of active s~st~ce aggl~t~, and ~ Pst~ yeasV
Skin tree celll.ir~ale in a ratio2:1- 10% 65,8 79,5 79,9 From Table, it is clearly app~cnt that even 10% of fluorocarbon aggregate and 10%
~lig~q5tion l~r~lu~l of the MP~ir~n skin tree result in a dear i~ ~ of the o~cygen content to a value wnich is close to that of a 25 % content of lluo~ l,an ag~al~. This is clear proof for the synergistic effect which is also su~polled by the 2~ lull~ of yeast and Sl~n tree ce~ i~gate.

Claims (15)

Claims

1. Functional oxygenaceous preparation, characterised by a content of a) phospholipids and an oxygen laden fluorocarbon or fluorocarbon mixture, the proportion of fluorocarbon being in the range of 0,2 to 100% weight/volume related to the fluorocarbon emulsion, and com-prising a phosphatidylcholine content of the lipid fraction of 30 to 99% by weight in the form of asymmetrical lamellar aggregates, having a skin penetration which is a function of the critical solu-bility temperature of the fluorocarbons.
b) a product obtained by the mild digestive treatment by means of ultrasonics and/or high pressure homogenisation up to 25MPa of suspensions or dispersions of cells of vegetable matter, bacteria or yeasts, and c) a cosmetic or dermatological carrier substance suitable for applica-tion to the skin.

2. A preparation according to claim 1, characterised in that the yeast is bakers' yeast, brewers' yeast, wine yeast or yeast enriched with peroxide dismutase.

3. A preparation according to claim 1, characterised in that the vege-table matter is the bark of the Mexican skin tree.

4. A preparation according to claim 1, characterised in that the vege-table matter is selected from green algae, seeds, grains, barks, plant extracts.

5. A preparation according to claim 1, characterised in that the dige-stion product contains one or more substances of the group of pro-teins such as peroxide dismutase, enzymes, nucleic acids, vitamins, fluoranoides, hormones, natural substances such as Aloe vera, rose-marin, camomile.

6. A preparation according to claim 1, characterised in that the dige-stion product contains combinations of fruit acids, e.g. malic acid, citric acid, tartaric acid, fumaric acid, succinic acid, gluconic acid as well as lactic acid.

7. A preparation according to claim 1, characterised in that the dige-stion product contains vitamins comprising the vitamin combinations P-B-A or A-E-C or B-E.A.

8. A preparation according to claim 1, characterised in that the fluo-rocarbons are selected from the group consisting of aliphatic straight chain and branched chain fluoroalkanes, mono- or bicyclic and optionally fluoroalkyl substituted fluorocycloalkanes, perfluo-rinated aliphatic or bicyclic amines, bis-(perfluoroalkyl)-ethenes or their mixtures.

9. A preparation according to claim 1, characterised in that the pro-portion of fluorocarbons is in the range of 20 to 100% w/v, prefera-bly in the range of 40 to 100%, based on fluorocarbon emulsion.

10. Process for the manufacture of a functional oxygenaceous prepara-tion, characterised in that (a) suspensions or dispersions of cells of vegetable matter, bacteria or yeasts are digestively treated by mild ultrasonic treatment and/or high pressure homogenisation up to 25 MPa, (b) phospholipids are emulsified with an oxygen-laden fluorocarbon or fluorocarbon mixture in an aqueous medium, the fluorocarbon content being in the range of 0,2 to 100% weight/volume related to the fluorocarbon emulsion, and the content of phosphatidylcholine in the lipid fraction amounting to 30 to 99 mass %.
(c) the digestive treatment product of (a) being mixed with the emulsion (b), and (d) the asymmetrical lamellar aggregates obtained by (c) which incorpo-rate the digestive treatment products (a) are incorporated in a carrier suitable for application to the skin.

11. Process according to claim 10, characterised in that the digestive treatment product is obtained by an ultrasonic digestive treatment using an ultrasonic continuous flow cell in which the sonotrode projects as to to 2/3 its length into the continuous flow cell, the angle of the sonotrode in the sound exposure vessel being in the range of 80,5 to 88,5°, the ratio of immersion length of the sono-trode (in mm) to the sound irradiated volume (in ml) being set to a value in the range of 1:1,1 to 1:20 and the ratio of immersion length of the synotrode (in mm) to the solids content of the medium to be irradiated ultrasonically (in mass %) being in the range of 0:0,02 to 1:2,2.

12. Process according to claim 11, characterised in that the solids concentration present in the medium to be subjected to ultrasonic treatment is in the range of 0,5 to 65 mass %.

13. Process according to claim 10, characterised in that the particle size of the asymmetrical lamellar aggregates is in the range of 50 to 1000 nm, preferably in the range of 120 to 820 nm, in particular in the range of 140 to 400 nm.

14. Use of a functional oxygenaceous preparation, comprising a) phospholipids and an oxygen laden fluorocarbon or fluorocarbon mixture, the proportion of fluorocarbon being in the range of 0,2 to 100% weight/volume, and comprising a phosphatidylcholine content of the lipid fraction of 30 to 99% by weight in the form of asymmetrical lamellar aggregates, b) a product obtained by the mild digestive treatment by means of ultrasonics and/or high pressure homogenisation up to 25 MPa of suspensions or dispersions of cells of vegetable matter, bacteria or yeasts, and c) a cosmetic or dermatological carrier substance suitable for application to the skin for the simultaneous supply of the skin with oxygen and with one or more substances of the group nutrients, active substances, protective agents and pharmaceutically active substances for the skin and/or the tissue underneath theskin.

15. Use according to claim 14, characterised in that it is practiced with appropriate carrier substances in the form of skin-care agents, sun protection formulations with UV absorbers, tanning agents, fat replenishing after-shaves, cleansing lotions and oils, encapsulated radical capturing agents, formulations against pregnancy stretch marks, hair and scalp care agents, bath oils, fitness friction agents, dermatological formulations with or without further pharmaceutically active substances.